Product Certification&
    Enterprise Certification

  • Mr.Xie
    Tel: +86-592-5853819

  • Ms.Serein Yan
    Region Sales Manager
    Tel: +86 0592 5887162

  • Ms.Coco Lv
    Region Sales Manager
    Tel: 0086-592-5881075

  • Ms.Penny Pan
    Region Sales Manager
    Tel: 0086-592-5881087

  • Ms.Shirley Shi
    Region Sales Manager
    Tel: +8613666090822

  • Ms.Denise Lai
    Region Sales Manager
    Tel: 0086-592-5887167

  • Mr.Duncan Deng
    Region Sales Manager
    Tel: +8617750663255

  • Ms.Susie Yan
    Region Sales Manager
    Tel: +8618060975837

  • Ms.Annette Wang
    Region Sales Manager
    Tel: +8615882299465

  • Mobile:+86 13806035118
  • Tel:+86-592-5853819
  • Fax:+86-592-5854960
  • URL:http://www.china-sinoway.com
  • Province/state:fujian
  • City:Xiamen
  • Street:16/F,Huicheng Comm,Complex,No839 XiaHe Rd, Xiamen,China
  • MaxCard:
Home > Products >  factory supply DMF Tofacitinib

factory supply DMF Tofacitinib CAS NO.540737-29-9

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,Other
  • Product Details

Keywords

  • Tofacitinib citrate
  • Tofacitinib
  • 540737-29-9

Quick Details

  • ProName: factory supply DMF Tofacitinib
  • CasNo: 540737-29-9
  • Molecular Formula: C16H20N6O.C6H8O7
  • Appearance: White crystallization
  • Application: Treating rheumatoid arthritis
  • DeliveryTime: in two weeks
  • PackAge: 25kg/drum
  • Port: SHANGHAI BEIJING
  • ProductionCapacity: 10 Metric Ton/Day
  • Purity: USP/EP/BP
  • Storage: room temperature
  • Transportation: AIR SEA TRAIN
  • LimitNum: 1 Kilogram

Superiority

We are very compeitive on Tofacitinib citrate.Our mfr is with DMF document. 

Product Name: Tofacitinib citrate
CAS: 540737-29-9
MF: C16H20N6O.C6H8O7
MW: 504.497
EINECS: 638-826-4
Product Categories: Inhibitor;API;Inhibitors;JAK;STAT;APIs
Mol File: 540737-29-9.mol
 

Details

Tofacitinib citrate Usage And Synthesis
Description Tofacitinib citrate is a king of drugs developed by the US pharmaceutical company for treating rheumatoid arthritis, trade name Xeljanz, for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid arthritis (RA) in adult patients. This product is a Janus kinase inhibitor, administered twice daily.
November 6, 2012, the US Food and Drug Administration (FDA) and Pfizer jointly announced Tofacitinib citrate is approved for the treatment of methotrexate inadequate response or intolerance to severe active rheumatoid joints arthritis (RA) in adult patients.
Xeljanz can be used as monotherapy or in combination with methotrexate or other non-biological disease-modifying antirheumatic drugs (the DMARD) in combination. This medicine should not be in combination with biological DMARD or strong immunosuppressants (such as cyclosporine and azathioprine). Xeljanz is approved by the daily dose of 2 times, each time 5mg.
Seven clinical trials evaluated the safety and efficacy of Tofacitinib citrate in moderate to severe active RA in adult patients. In all tests, compared with patients receiving placebo, patients receiving Xeljanz treatment showed significant improvement in clinical response and physical function.
In Clinical trials, the most common adverse events were upper respiratory tract infection, headache, diarrhea, nasal congestion, sore throat, and nasopharyngitis.
Using Xeljanz was associated with an increased risk of serious infections, including opportunistic infections, tuberculosis, cancer and lymphoma. Xeljanz product label attaches boxed warning on these security risks. Xeljanz treatment is also associated with reducing blood cell counts and increasing cholesterol and liver enzyme values.
In order to study Xeljanz long-term impact on heart disease, cancer and severe infections, FDA requires for a post-marketing study, which will evaluate two doses of Xeljanz (Tofacitinib citrate) therapy, and accept a integration of another group of patients approved by the treatment as a control.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog